What PPMI’s Pre-Symptomatic Parkinson’s Cohort Teaches Sites About Biomarker-Driven Screening
PPMI's RBD and hyposmia enrollment strategy yields 94% CSF alpha-synuclein positivity, here's what that means for site screening workflows...
EMA and AMA’s Joint Ebola Vaccine Guidance Is a Regulatory Harmonization Blueprint Sponsors Can’t Afford to Miss
EMA and AMA issued joint Ebola vaccine guidance in 2026, offering the clearest cross-regional regulatory harmonization framework for accelerated...
Enanta’s RESOLVE Trial Just Started. Your Site’s RSV Readiness Hasn’t.
Enanta dosed its first RESOLVE patient Oct 26. High-risk adult RSV outpatient capacity is already strained, here's what site...
Hengrui Pharma Presents 64 Studies at ESMO 2026, Record for Chinese Oncology Company
Hengrui Pharma presents 64 studies at ESMO 2026, a record for the Chinese oncology company showcasing 14 approved innovative...
Atrium Therapeutics Doses First Patient in ATR-1072 Trial for PRKAG2 Syndrome
Atrium Therapeutics doses first patient in ATR-1072 trial for PRKAG2 syndrome, targeting the genetic cause of cardiac disease.
Zemprocitinib Maintains ACR20 Response in 90% of RA Patients at 76 Weeks
Zemprocitinib maintains ACR20 response in 90% of RA patients at 76 weeks in Phase III trial, with consistent safety...
Qutenza meets primary pain endpoint in post-surgical neuropathy trial
Qutenza meets primary pain endpoint in post-surgical neuropathy trial, showing sustained benefit over ten months in extension phase.
AI Is Already Inside the Doctor’s Visit. The Question Is Whether It’s Helping or Hunting for Billable Findings.
More than half of physicians now use clinical AI regularly, but new data shows AI systems ordered tests at...
A Patient Died in BMS’s MS CAR-T Trial. No One Can Say Why.
A Phase 1 multiple sclerosis patient died 44 days after a zola-cel infusion. BMS says confounding factors prevent it...
Same Protocol, Different State, Different Answer: How Regional Coverage Breaks Multi-Site MCAs
MAC discretion means the same lab draw can be covered at one site and not another. Here is how...